# 2025-21689: FDA Updates Rules for Safe Medical Gas Production

2025-21689, Medical Gases-Current Good Manufacturing Practice; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-12-01, effective 2025-12-18 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-21689
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-21689
- Title: Medical Gases-Current Good Manufacturing Practice; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 55131
- Published: 2025-12-01
- Effective: 2025-12-18
- Comments close: 2026-01-30
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Updates Rules for Safe Medical Gas Production

## Summary

The FDA just dropped a new draft guide to help medical gas makers follow updated safety and quality rules starting December 18, 2025. This affects anyone making gases for humans or animals, aiming to keep products pure and safe while cutting down on red tape. If you’re in the biz, get ready to review and comment by January 30, 2026, so your voice shapes the final rules!

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Medical Gases--Current Good Manufacturing Practice." This guidance is intended to assist manufacturers of medical gases in complying with regulations for current good manufacturing practice (CGMP) that become effective on December 18, 2025 (note, the conforming amendments to the CGMP requirements for combination products became effective February 2, 2026). These regulations are specific to medical gases for human and animal use and, like all CGMP requirements, contain the minimum requirements to ensure that manufacturing processes operate under a state of control to meet prespecified quality standards for identity, strength, quality, and purity, but are tailored more narrowly to how medical gases are manufactured, packaged, labeled, stored, and distributed. This draft guidance is being issued to reflect new and revised regulations in several areas to reduce the regulatory burden, as appropriate, for the medical gas industry. This draft guidance revises and replaces the draft guidance entitled "Current Good Manufacturing Practice for Medical Gases" issued in June 2017.

## Effects PRIA read

- Medical-gas CGMPs take effect: benefit, medium. If you manufacture medical gases for people or animals, new medical-gas-specific good manufacturing practice rules take effect on December 18, 2025, and those rules (part 213) replace the general drug CGMP rules in parts 210 and 211. Conforming amendments for combination products became effective F…
- Guidance clarifies key compliance areas: benefit, medium. FDA issued a draft guidance (revising the June 2017 draft) to explain how to comply with the new medical-gas CGMPs. The draft guidance includes recommendations and clarifications on ensuring supplier reliability, protecting against container closure leaks, cleaning and equipment maintenance, preven…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-21689 on federalregister.gov](https://www.federalregister.gov/documents/2025/12/01/2025-21689/medical-gases-current-good-manufacturing-practice-draft-guidance-for-industry-availability)
- [2025-21689 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-12-01/pdf/2025-21689.pdf)

## Related
- [Previous: 2025-21688, Agency Information Collection Activities; Proposed eCollection eComments Reques…](https://policyrisk.com/federal-register/2025-21688)
- [Next: 2025-21690, Agency Information Collection Activities: Submission for OMB Review; Comment Re…](https://policyrisk.com/federal-register/2025-21690)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-21689 (as of 2026-06-08).
